Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 6/20 | 0.57 |
| ▸ | SSTR2 | P30874 | 6/20 | 0.57 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.57 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.57 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.52 |
| ▸ | CDC25B | P30305 | 7/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8507196 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6139789 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL15444989 | 0.89 | SSTR4 (0.47) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7908620 | 0.88 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7908639 | 0.88 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6545135 | 0.88 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7908611 | 0.88 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7908607 | 0.88 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7908613 | 0.88 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6545131 | 0.88 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1088558-B1 | Galenic formulations comprising paramagnetic and diamagnetic compounds | BAYER SCHERING PHARMA AG (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060093554-A1 | Galenical formulations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| EP-1307236-A2 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MR-IMAGING FOR THE REPRESENTATION OF PLAQUES, TUMOURS AND NECROSES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-07 | — | — | EP | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| WO-2002013874-A2 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MR-IMAGING FOR THE REPRESENTATION OF PLAQUES, TUMOURS AND NECROSES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
| EP-1088558-A2 | Galenic formulations | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | SSTR1 236/4885SSTR2 788/4885SSTR4 767/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | SSTR1 54/4885SSTR2 377/4885SSTR4 322/4885 |
| US-20060093554-A1 | Galenical formulations | GALC, GALR2, GALR1 | SSTR1 217/4885SSTR2 277/4885SSTR4 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.